Our perspectives
in one place
Topic
Selected filters
Clear
News
See allIndividual statement at WHA76 on agenda items 13.1 and 13.2
On 26 May, IFPMA provided a WHA76 statement on agenda items 13.1: Reorienting health systems to primary health care as a resilient foundation for universal health coverage and preparations for a high-level meeting of the United Nations General Assembly on universal health coverage and 13.2: Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases, and mental health.
Read moreIndividual statement at WHA76 on agenda item 15.1
On 24 May, during the 76th World Health Assembly in Geneva, IFPMA delivered a statement on agenda item 15.1: Strengthening the global architecture for health emergency preparedness, response, and resilience.
Read more
IFPMA and Speak Up Africa launch 2nd edition of flagship award program supporting young health innovators across Africa
Read moreIFPMA statement at the Multi-stakeholder Hearing on Universal Health Coverage
On 9 May, IFPMA read the following statement at the Multi-stakeholder Hearing on Universal Health Coverage (UHC) in New York.
Read moreIFPMA statement at the Multi-stakeholder Hearing on Pandemic Prevention, Preparedness, and Response
on 9 May, IFPMA read the following statement at the Multi-stakeholder Hearing on Pandemic Prevention, Preparedness, and Response in New York.
Read moreIFPMA statement for Multi-stakeholder Hearing on Tuberculosis
On 8 may, IFPMA read the following statement at the Multi-stakeholder Hearing on Tuberculosis (TB) in New York.
Read morePublications
See allIFPMA Note for Guidance on sponsorship of events and meetings (2023 update)
Collaborations between healthcare professionals (HCPs) and the pharmaceutical industry are essential and ensure that patients have access to the medicines they need and that healthcare professionals have up-to-date comprehensive information about the diseases they treat and the medicines they prescribe.
Read moreReinforcing collaboration on Universal Health Coverage to deliver greater global health equity and health security
The innovative pharmaceutical industry stands together with other members of the global health community to support countries in accelerating their efforts to achieve UHC. Read our position paper.
Read more
Key considerations on the scope, utility and processes around updating the WHO Essential Medicines List
The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.
Read moreExpert insights
See all
Clinical trials: Ethics, innovation, and how to achieve greater equity and equality
Read more
How Universal Health Coverage makes SDGs doable
Read more
The power of partnerships and innovation: Accelerating progress toward Universal Health Coverage by 2030
Read moreResources
See allAdvancing universal health coverage in Africa
Universal Health Coverage (UHC) is at the heart of the health-related Sustainable Development Goals (SDGs). It is the foundation for both global health security and the health and well-being of all people throughout their lifetimes. Africa’s health systems are essential in delivering the UHC2030 action agenda. Given Africa’s population is expected to double by 2050,...
Read more
Collaborating to achieve universal health coverage
Discover how the innovative pharmaceutical industry is embracing partnerships to accelerate action on SDG 3 and other global goals in this infographic.
Read more
Collaborating for Global Health Progress flyer
Discover how the innovative pharmaceutical industry works with partners to advance the SDGs
Read more